About

About Neogap Therapeutics Neogap Therapeutics is a clinical-stage immuno-oncology company developing personalized, non-engineered T-cell therapies targeting solid tumors. Its PIOR® and EpiTCer® platforms enable selective expansion of neoantigen-specific T cells, addressing key limitations of current cell therapies in solid cancers. Its lead asset, pTTL, is in Phase I/IIa in metastatic colorectal cancer with encouraging safety and persistence. With a scalable manufacturing strategy and strong IP portfolio, Neogap is positioned for partnering across clinical development, manufacturing, and next-generation IO combinations.